Is AbbVie's Imbruvica concerned about AZ's rising Calquence? We've got this covered, execs say

AbbVie has a lot on its plate with a megamerger with Allergan in the works and the rollout of blockbuster hopeful Rinvoq. One thing it hasn't had to worry about much is its blood cancer franchise––and, despite a rising challenger in AstraZeneca's Calquence, AbbVie still isn't concerned.